Teva Pharmaceutical Industries (TEVA) FCF Margin (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly FCF Margin came in at 7.41% in Q2 2026, up 427.0% on a YoY basis from 1.41% in Q2 2025, and up 241.89% quarter-over-quarter from 5.22% in Q1 2026.
Powered by 
Analysis
Teva Pharmaceutical Industries (TEVA) FCF Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported FCF Margin for 18 consecutive years, with 7.41% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin rose 427.0% year-over-year to 7.41%; the trailing twelve-month figure through Jun 2026 stood at 7.79% (up 197.0% YoY), and the FY2025 full-year result was 6.65%, up 212.0% from the prior year.
- FCF Margin improved to 7.41% in Q2 2026 per TEVA's latest filing, from 5.22% in the prior quarter.
- Across five years, FCF Margin topped out at 23.89% in Q4 2023 and bottomed at 7.76% in Q1 2023.
- Historically, FCF Margin has averaged 5.16% across 5 years, with a median of 4.17% in 2025.
- The sharpest annual moves came in 2023 and 2024: FCF Margin tumbled 1545 bps in 2023, then surged 1632 bps in 2024.
- Over 5 years, FCF Margin stood at 21.4% in 2022, then increased by 12 bps to 23.89% in 2023, then sank by 36 bps to 15.38% in 2024, then surged by 40 bps to 21.57% in 2025, then sank by 66 bps to 7.41% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 7.41%, 5.22%, and 21.57% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | 7.41% |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn | 8.76% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 3.10% |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn | -6.52% |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 20.79% |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | 14.76% |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 20.15% |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 23.24% |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.41% |
| Mar 31, 2026 | -5.22% |
| Dec 31, 2025 | 21.57% |
| Sep 30, 2025 | 5.20% |
| Jun 30, 2025 | 3.14% |
| Mar 31, 2025 | -5.96% |
| Dec 31, 2024 | 15.38% |
| Sep 30, 2024 | 12.58% |
| Jun 30, 2024 | 0.14% |
| Mar 31, 2024 | -6.49% |
| Dec 31, 2023 | 23.89% |
| Sep 30, 2023 | -3.74% |
| Jun 30, 2023 | 5.29% |
| Mar 31, 2023 | -7.76% |
| Dec 31, 2022 | 21.40% |
| Sep 30, 2022 | 11.71% |
| Jun 30, 2022 | -0.11% |
| Mar 31, 2022 | -5.63% |
| Dec 31, 2021 | 7.39% |
| Sep 30, 2021 | 9.85% |